Franklin Berger

Franklin Berger

Directeur/Membre du Conseil chez ATEA PHARMACEUTICALS, INC.

Fortune : 7 M $ au 31/10/2026

76 ans
Health Technology
Finance
Consumer Services

Profil

Mr. Franklin M.
Berger
, CFA MBA, is an Independent Director at Retension Pharmaceuticals, Inc., a Lead Independent Director at Atea Pharmaceuticals, Inc., a Senior Advisor at Qiming US Ventures Management, LLC and a Managing Director at FMB Research.
He is on the Board of Directors at Retension Pharmaceuticals, Inc., Satellos Bioscience, Inc., Atea Pharmaceuticals, Inc. and Walking Fish Therapeutics, Inc. Mr. Berger was previously employed as a Lead Independent Director by Rain Oncology, Inc., a Chairman by Proteostasis Therapeutics, Inc., an Independent Director by ESSA Pharma, Inc., an Independent Director by Atreca, Inc., an Independent Director by Tocagen, Inc., an Independent Director by Immune Design Corp., an Independent Director by BioTime, Inc., an Independent Director by Five Prime Therapeutics, Inc., an Independent Director by BELLUS Health, Inc., a Lead Independent Director by Thallion Pharmaceuticals, Inc., a Senior Manager-Portfolio by NEMO Fund, Inc., a Senior Manager-Investment by Sectoral Asset Management, Inc., an Independent Director by Seattle Genetics, Inc., a Managing Director-Equity Research by JPMorgan Securities, Inc., a Managing Director-Equity Research by Salomon Smith Barney, Inc., a Director-Equity Research by Smith Barney Asset Management, a Managing Director-Equity Research by Josephthal, Lyon & Ross, Inc., and an Advisor by Brookline Capital Acquisition Corp.
He also served on the board at Applied Therapeutics, Inc., Kezar Life Sciences, Inc., Emisphere Technologies, Inc., Isotechnika Pharma, Inc., Isotechnika, Inc., VaxGen, Inc., Alzheon, Inc., Asterias Biotherapeutics, Inc., Aurinia Pharmaceuticals, Inc., Caprion Proteomics, Inc., CellCarta Biosciences, Inc., Episcopal Relief & Development Corp., HealthShares, Inc., iTherX Pharmaceuticals, Inc., The Genetics Co., Inc. and ViroChem Pharma, Inc.

Détentions connues dans des sociétés publiques

SociétéDateNombre d'actionsValorisationDate de valorisation
18/08/2026 690 067 ( 3,25 % ) 5 M $ 31/10/2026
18/06/2026 536 097 ( 0,67 % ) 2 M $ 31/10/2026
0,27 %
13/10/2026 22 517 ( 0,27 % ) 255 793 $ 31/10/2026

Postes actifs de Franklin Berger

SociétésPosteDébut
ATEA PHARMACEUTICALS, INC. Directeur/Membre du Conseil 01/09/2019
SATELLOS BIOSCIENCE INC. Directeur/Membre du Conseil 29/06/2023
Directeur Général 01/06/2005
Directeur/Membre du Conseil -
Consultant / Advisor 01/01/2019

Anciens postes connus de Franklin Berger

SociétésPosteFin
KEZAR LIFE SCIENCES, INC. Directeur/Membre du Conseil 11/05/2026
ESSA PHARMA INC. Directeur/Membre du Conseil 09/10/2025
ATRECA, INC. Directeur/Membre du Conseil 13/05/2024
RAIN ONCOLOGY INC. Directeur/Membre du Conseil 25/01/2024
░░░░░░ ░░░░░░ ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ ░░░░░░░░░░
Voir l'expérience en détail de Franklin Berger

Formation de Franklin Berger

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Relations

65

Relations au 1er degré

41

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Sociétés liées

Entreprise privées41

Health Technology

Health Technology

Distribution Services

Health Technology

Health Technology

Health Technology

Health Technology

Finance

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Finance

Finance

Finance

Consumer Services

Health Technology

Miscellaneous

Health Technology

Commercial Services

Health Technology

Health Services

Health Technology

Finance

Health Technology

Commercial Services

NEMO Fund, Inc.

Health Technology

Health Technology

Consumer Services

Health Technology

Miscellaneous

Health Technology

Health Technology

Health Technology

Finance

Health Technology

Finance

Health Technology

  1. Bourse
  2. Insiders
  3. Franklin Berger
🔇